Gastric cancer (GC) is an important cause of cancer worldwide with over one million new cases yearly. The vast majority of cases present in stage IV disease, and it still bears a poor prognosis. However, since 2010, progress has been made with the introduction of targeted therapies against HER2 and with checkpoint inhibitors (PDL1). More agents interfering with other targets (FGFR2B, CLDN18.2) are being investigated. cMET is a less frequent molecular target that has been studied for gastric cancer. It is a proto-oncogene that leads to activation of the MAPK pathway and the PI3K pathway, which is responsible for activating the MTOR pathway. The prevalence of cMET is strongly debated as different techniques are being used to detect MET-driven tumors. Because of the difference in diagnostic assays, selecting patients who benefit from cMET inhibitors is difficult. In this review, we discuss the pathway of cMET, its clinical significance and the different diagnostic assays that are currently used, such as immunohistochemy (IHC), fluorescence in situ hybridization (FISH), the H-score and next-generation sequencing (NGS). Next, we discuss all the current data on cMET inhibitors in gastric cancer. Since the data on cMET inhibitors are very heterogenous, it is difficult to provide a general consensus on the outcome, as inclusion criteria differ between trials. Diagnosing cMET-driven gastric tumors is difficult, and potentially the only accurate determination of cMET overexpression/amplification may be next-generation sequencing (NGS).
Fibroblast activation protein (FAP)-binding radiopharmaceuticals have emerged as promising candidates for both diagnostic and therapeutic applications in oncology due to their selective targeting of cancer-associated fibroblasts (CAFs). This review evaluates the current literature on the therapeutic use of FAP-targeted radiopharmaceuticals in human studies, with a focus on their safety, efficacy, and clinical applicability. Data on radionuclide type, clinical outcome, radiological and metabolic response and adverse events were extracted and summarized. The included studies demonstrated that lutetium-177,yttrium-90 and actinium-225 (in combination therapy) labeled FAP inhibitors exhibit high tumor uptake, with varying but mostly sufficient retention and a favorable safety profile. While mild adverse events such as fatigue, nausea and grade 1 or 2 hematotoxicity were observed, severe toxicities were rare. FAPI-based radionuclide therapies generally show high disease control rates, with promising results from tandem and combination strategies. The heterogeneity of tumor types and small sample sizes limited the generalizability of findings. FAP-targeted radioligand therapy appears to be a promising treatment option for patients with advanced cancer who have exhausted standard therapies. However, further large-scale, prospective clinical trials are necessary to determine optimal dosing strategies, long-term safety and efficacy across different tumor types. Emerging approaches, such as covalently binding FAP-targeted radiopharmaceuticals and the use of alpha-emitters such as actinium-225, lead-212 and bismuth-213, may further enhance treatment outcomes and warrant future investigation.
Fibroblast growth factor receptor 2 isoform IIIb (FGFR2b) protein overexpression is an emerging biomarker and a potential therapeutic target in gastric and gastroesophageal junction cancers (G/GEJC). Limited data exist on the global prevalence of FGFR2b overexpression in advanced G/GEJC using a validated assay. We assessed the prevalence of FGFR2b protein overexpression in a pooled analysis of tumor samples collected as part of the prescreening process for two global phase III studies of bemarituzumab as first-line treatment for locally advanced or metastatic G/GEJC. As of 20 February 2025, 7910 tumor samples from patients prescreened for enrollment in the FORTITUDE-101 (NCT05052801; n = 3752) and FORTITUDE-102 (NCT05111626; n = 4158) studies were centrally tested for FGFR2b protein overexpression by immunohistochemistry (IHC) and had evaluable results. FGFR2b overexpression was defined as both any percentage (>0%) of tumor cells (TCs) and ≥10% of TCs exhibiting moderate (2+) to strong (3+) membrane staining of FGFR2b. Prevalence was analyzed across defined patient and sample characteristics. The estimated prevalence of FGFR2b any 2+/3+ was 36.5% [95% confidence interval (CI) 35.4-37.6; 2887/7910] and that of FGFR2b ≥10% 2+/3+ was 16.6% (95% CI 15.7-17.4; 1310/7910). Prevalence estimates from this pooled analysis and a separate analysis for FORTITUDE-102 [any 2+/3+: 35.8% (95% CI 34.3-37.2); FGFR2b ≥10% 2+/3+: 17.3% (95% CI 16.1-18.4)] were consistent with results previously reported for FORTITUDE-101 (Rha SY, Zhang Y, Elme A, et al. Prevalence of FGFR2b protein overexpression in advanced gastric cancers during prescreening for the phase III FORTITUDE-101 trial. JCO Precis Oncol. 2025;9:e2400710). FGFR2b prevalence was consistent across patient and sample characteristics [age, sex, collection method (biopsy versus resection), collection site, location of primary tumor, and geographic region]. This study represents the largest prevalence assessment of FGFR2b overexpression in G/GEJC using a validated IHC assay. The observed estimates of 36.5% (any 2+/3+) and 16.6% (FGFR2b ≥10% 2+/3+) suggest that FGFR2b is prevalent in a meaningful proportion of patients with advanced G/GEJC.
In the era of immune checkpoint inhibitors for cancers, the need for prognostic biomarkers to identify patients most likely to achieve a durable response has become increasingly more relevant. Tumour‐infiltrating lymphocytes (TILs) have gained significant interest, as they can be evaluated using standard haematoxylin and eosin‐stained slides, making it a widely accessible and cost‐effective biomarker. In addition to their practicality, TILs provide prognostic insights into the interplay between the immune system and tumour cells. While the morphological assessment of TILs has been standardised in breast cancer, comprehensive guidelines for their evaluation in gastro‐oesophageal carcinomas (GEC) are still lacking. This narrative review examines the current literature on the composition, clinical implications and therapeutic utility of TILs in GEC. These insights are used to propose a framework with recommendations for standardised evaluation and reporting of TILs in GEC, while also highlighting pitfalls specific to GEC pathology. These recommendations serve as a vital first step towards the widespread use and validation of TILs as a biomarker.